Deferasirox

證據等級: L5

預測適應症: 5 個

Deferasirox: From Chronic Iron Overload to HIV Infectious Disease

One-Sentence Summary

Deferasirox is an oral iron chelating agent originally developed and approved internationally for the treatment of chronic iron overload caused by blood transfusions or non-transfusion-dependent thalassaemia. The TxGNN model predicts it may be effective for HIV Infectious Disease, with 0 clinical trials and 2 publications currently supporting this direction. The mechanistic hypothesis is biologically plausible but remains at an early, unvalidated stage.

Quick Overview

Item	Content
Original Indication	Chronic iron overload (transfusion-dependent)
Predicted New Indication	HIV Infectious Disease
TxGNN Prediction Score	99.40%
Evidence Level	L4
Taiwan Market Status	✗ Not Marketed
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Deferasirox is a tridentate oral iron chelator that works by binding free iron (Fe³⁺) with high selectivity, forming stable complexes that are excreted primarily via the faeces. It is used to reduce chronic iron overload in patients who require regular blood transfusions (e.g., beta-thalassaemia, sickle cell disease, myelodysplastic syndromes).

The connection to HIV infectious disease rests on an indirect mechanistic hypothesis: iron plays a critical role in HIV-1 replication. Research has demonstrated that endolysosomal iron can facilitate HIV-1 Tat protein oligomerisation and subsequent LTR transactivation — a key step in viral replication. By depleting intracellular iron in endolysosomes, Deferasirox may theoretically disrupt this step, suppressing HIV-1 replication without directly targeting the virus.

However, this remains a mechanistic hypothesis derived from in vitro studies and has not been validated in cell infection models, animal studies, or human trials. The original indication (iron overload) and the predicted indication (HIV) share no direct clinical overlap — the link is purely through the role of iron as a cofactor in viral biology. This is a biologically interesting but unproven hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
34550543	2021	In vitro mechanistic study	Journal of Neurovirology	Demonstrates that endolysosomal iron promotes HIV-1 Tat oligomerisation and LTR transactivation; low-iron conditions suppress Tat-mediated HIV-1 replication — provides the mechanistic rationale for iron chelation as a potential anti-HIV strategy
16529348	2006	Drug introduction review	Journal of the American Pharmacists Association	Overview of Deferasirox at its market launch; describes its approved indication for iron overload with no HIV-related findings

Taiwan Market Information

Deferasirox is currently not marketed in Taiwan. No drug identification numbers (DINs) have been issued. Therefore, no Taiwan regulatory licence data is available for this drug.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this evidence pack. Before any clinical or research use of Deferasirox, refer to the current prescribing information. Key known safety concerns from global regulatory approvals (not from this evidence pack) include renal impairment, hepatic toxicity, gastrointestinal reactions, and auditory/visual disturbances — these should be reviewed before protocol design.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic hypothesis linking iron chelation to HIV-1 suppression is biologically interesting but supported only by a single in vitro study. There are no clinical trials and no clinical observational data. The evidence level (L4) and the absence of Taiwan regulatory approval make this a research-stage hypothesis only — it is not ready to advance to safety or efficacy evaluation.

To proceed, the following is needed:

MOA validation: Conduct or identify in vitro HIV infection model studies (not just mechanistic cell-free assays) to confirm whether Deferasirox at clinically relevant concentrations reduces HIV replication
Preclinical data: Animal model studies demonstrating antiviral activity before any human research is considered
Safety profile retrieval: Obtain full prescribing information (package insert) to complete safety screening (S1 gate) — this is currently a blocking data gap
Regulatory status clarification: Determine whether compassionate use or research IND pathways are available given the drug is not marketed in Taiwan
Literature scan expansion: Search for more recent publications on iron chelation and HIV, including any studies with Deferoxamine or other chelators that may provide supporting class evidence
Comparison with antiretroviral alternatives: Any further development must be benchmarked against the high efficacy of current HIV treatment (ART), which sets a very high bar for any adjunctive or alternative strategy
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.